

Cancer Core Europe Lecture

Presented by Education & Training Task Force

SPEAKER

Fanny Jaulin

Team Leader
U1279 (with Inserm and Paris-Saclay university)
at Gustave Roussy, Villejuif, France



Patient derived organoids as decision making tools in precision oncology

Date: Thursday, November 13, 2025 - Time: 15:00-16:00 CET



Our consortium of 8 partners from public and private backgrounds uniquely combines expertise in organoid biology, micro-engineering, artificial intelligence, and large-scale clinical validation. Together, we have the ambition to establish PDO-based assays, "organograms", as clinically robust tools for personalized treatment decisions in colorectal and pancreatic cancer. By creating 3D tumor models that closely mimic the patient's original tumor, the program enables the testing of various treatments to identify the most effective options for individual patients.

The key objectives are:

- Personalized Treatment Prediction: Utilize PDOs to predict patient responses to treatments, including chemotherapy and immunotherapy.
- Clinical Integration: Develop protocols for incorporating PDO-based testing into routine clinical practice.
- Data-Driven Insights: Employ advanced imaging and data analysis techniques to enhance the predictive power of PDO models.

Dr. Fanny Jaulin

Director of Research at Inserm and team leader at Gustave Roussy, within Université Paris-Saclay, Dr. Jaulin heads the "Collective Invasion" team, which explores how groups of cancer cells migrate and invade tissues together, a key process in tumor progression and metastasis. Her research bridges cell biology, organoid modeling, and translational oncology, with a particular focus on digestive cancers. She also serves as the scientific coordinator of the RHU ORGANOMIC program, which aims to use patient-derived organoids to guide clinical decisions and develop more effective, personalized cancer treatments. In parallel, Dr. Jaulin is the CEO and co-founder of Orakl Oncology, a biotechnology company translating organoid-based discoveries into clinical applications.

ROUSSY-

CANCER CAMPUS

Hosted by:

